This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy. Hypocalcemia is a known risk of bisphosphonate treatments, but the incidence of severe hypocalcemia is rare, and the risk factors are well established. However, in the treatment of hypercalcemia of malignancy, the treatment objective is to reduce the elevated serum calcium level, and the bisphosphonate is usually given as one time dose only. The potential for developing severe hypocalcemia may not be considered a significant concern in this setting compared to the setting of the treatment of bone metastasis, where the baseline serum calcium level is not elevated and the bisphosphonate is administered at a regular interval of every three to four weeks. Furthermore, there is unawareness of prevalence of vitamin D deficiency in cancer patients, especially in those with advanced cancer, which may lead to inadvertent, severe hypocalcemia from bisphosphonate treatment. The objective of this case report is to bring awareness to the risk of severe hypocalcemia in patients with hypercalcemia of malignancy and the high prevalence of unrecognized vitamin D deficiency in cancer patients.
RoelofsAJThompsonKGordonS, et al.Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res2006; 12: 6222s–6230s.
2.
GoldsteinDA. Serum calcium [Chapter 143]. In: Walker HK, Hall WD, Hurst JW (eds) Clinical methods: the history, physical, and laboratory examinations, 3rd ed. Boston: Butterworths, 1990. .
3.
SternlichtHGlezemanIG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag2015; 11: 1779–1788.
4.
DunfordJEThompsonKCoxonFP, et al.Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther2001; 296: 235–242.
5.
GreenJRMüllerKJaegggiKA. Preclinical pharmacology of CGP 42446 a new potent heterocyclic bisphosphonate compound. J Bone Miner Res1994; 9: 745–751.
6.
SimsECRogersPBBesserGM, et al.Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Clin Oncol1998; 10: 407–409.
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Hypocalcemia. U.S. Dept of Health and Human Services, National Institute of Health, National Cancer Institute, 12 June 2010.
Lexicomp. Calcium gluconate, www.online.lexi.com (accessed 11 September 2016).
13.
Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press. https://doi.org/10.17226/13050. (2011, accessed 5 November 2018).
14.
NarechaniaSThiruchelvamNLokhandC, et al.Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy. J Community Support Oncol2015; 13: 374–377.
15.
FraserWDLogueFCGallacherSJ, et al.Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Bone Miner1991; 12: 113–121.
16.
PeterRMishraVFraserWD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ2004; 328: 335–336.
17.
ChampallouCBasuyauJPVeyretC, et al.Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. J Pain Symptom Manage2003; 25: 185–190.
18.
CömlekçiABiberogluSHekimsoyZ, et al.Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. Intern Med1998; 37: 396–397.
19.
MishraAWongLJonklassJ. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine2001; 14: 159–164.
20.
NarechaniaSThiruchelvamNLokhandeC, et al.Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy. J Community Support Oncol2015; 13: 374–377.
21.
MishraA. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient. J Postgrad Med2008; 54: 237.
22.
HenleyDKayeJWalshJ, et al.Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Intern Med J2005; 35: 726–728.
23.
KreutleVBlumCMeierC, et al.Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature. Swiss Med Wkly2014 Jun 25; 144:w13979. doi: 10.4414/smw.2014. 13979. eCollection 2014.
24.
MaaloufNMHellerHJOdvinaCV, et al.Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract2006; 12: 48–53.
25.
BreenTLShaneE. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol2004; 22: 1531–1532.
26.
BroadbentAGlarePCrawfordB. Bisphosphonate-induced hypocalcemia associated with vitamin D deficiency in a patient with advanced cancer. Am J Hosp Palliat Care2005; 22: 382–384.
27.
HoJWSundarS. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?. Clin Genitourin Cancer2012; 10: 50–53.
28.
Noriega AldaveAPJaiswalS. Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report. J Med Case Rep2014; 8: 353.
29.
SinghDKhairaNSSekhonJS. Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma. Ann Oncol2004; 15: 1848.
30.
EpperlaNPathakR. Hypocalcemia secondary to zoledronate therapy in a patient with low vitamin D level. WMJ2015; 114: 163–166. quiz 167.
31.
Wang-GillamAMilesDAHutchinsLF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist2008; 13: 821–827.
32.
TangprichaVColonNAKaulH, et al.Prevalence of vitamin D deficiency in patients attending an outpatient cancer clinic in Boston [letter]. Endocr Pract2004; 10: 292–293.
33.
ThomasMKLloyd-JonesDMThadhaniRI, et al.Hypovitaminosis D in medical inpatients. N Engl J Med1998; 338: 777–783.
34.
SegalEFelderSHaimN, et al.Vitamin D deficiency in oncology patients – an ignored condition: impact on hypocalcemia and quality of life. Isr Med Assoc J2012; 14: 607–612.
